Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOPPLER study of methotrexate discontinuation after remission with upadacitinib plus methotrexate in rheumatoid arthritis
jRCTs071200079Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of upadacitinib and methotrexate in rheumatoid arthritis (RA), sponsored by AbbVie Inc. Primary endpoint: Sustained therapeutic response after methotrexate discontinuation. Started Mar 2021; status: recruiting.
02
Drugs
upadacitinibmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCTs071200079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071200079.